Generic Medicine Info
Known hypersensitivity. Should not be used in patients with clinically important infections.
Special Precautions
Monitor platelet counts before and during treatment. Acellular, live and live-attenuated vaccines should not be given during treatment. Pregnancy and lactation.
Adverse Reactions
Headache, fever, nausea, vomiting.
Drug Interactions
Avoid concurrent admin of other immunosuppressive agents or with phototherapy.
CIMS Class
ATC Classification
L04AA21 - efalizumab ; Belongs to the class of selective immunosuppressive agents. Used to induce immunosuppression.
Disclaimer: This information is independently developed by CIMS based on efalizumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in